Contact:
4008465777
Global Expansion | Tonghua Dongbao's Mixed Isophane Protamine Human Insulin Injection (30R) Approved for Marketing in Uzbekistan
Date：2025-03-23
Author：东宝
Views：0
Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company") recently received marketing approval for its Mixed Isophane Protamine Human Insulin Injection (30R) from the regulatory authorities of Uzbekistan. This approval marks the Company's official entry into the Uzbek market for human insulin injections and is expected to further expand its overseas sales potential.
Located in Central Asia, Uzbekistan is a key emerging market participating in the Belt and Road Initiative, with a large population and growing healthcare needs. As of October 2024, Uzbekistan had a total population of approximately 37.36 million. According to the 10th edition of the International Diabetes Federation (IDF) Global Diabetes Atlas (2021), there were about 1.3518 million diabetes patients aged 20 to 79 in Uzbekistan, with a prevalence rate of 6.3%. Among these, undiagnosed cases accounted for a high proportion, reaching 74%.
To seize overseas opportunities, the Company has leveraged its competitive strengths and implemented a differentiated expansion strategy, tailored to the market size, growth potential, healthcare system, medication needs, and treatment habits of each target country or region. Its human insulin products are primarily positioned for emerging markets and developing countries in the Belt and Road Initiative, with customized sales strategies based on local conditions.
As the Marketing Authorization Holder (MAH), the Company received the marketing license for Mixed Isophane Protamine Human Insulin Injection (30R) from the Ministry of Health of the Republic of Uzbekistan. This approval enriches the Company's international product portfolio, enhances its brand presence, expands its global business, and provides a replicable pathway for future overseas regulatory approvals. It is expected to accelerate the Company's expansion in emerging markets and Belt and Road countries and strengthen its competitiveness in the international market.
